The plant family Amaryllidaceae is recognizable for its esthetic floral characteristics, its widespread usage in traditional medicine as well as its unique alkaloid principles. Few alkaloid-producing families rival the Amaryllidaceae in terms of the diversity of its structures as well as their wide applicability on the biological landscape. In particular, cytotoxic effects have come to be a dominant theme in the biological properties of Amaryllidaceae alkaloids. To this extent, a significant number of structures have been subjected to in vitro studies in numerous cell lines from which several targets have been identified as promising chemotherapeutics. By contrast, in vivo models of study involving these alkaloids have been carried out to a lesser extent and should prove crucial in the continued development of a clinical target such as pancratistatin. This survey examines the cytotoxic effects of Amaryllidaceae alkaloids in vivo and contrasts these against the corresponding in vitro effects.
Plants of the family Amaryllidaceae have a long history of use for the remediation of cancer in the traditional medicine (TM) of indigenous peoples around the world [1] [2] [3] [4] . For example, Lycoris radiata has been recorded for such purposes in ancient Chinese TM [1] , while Hymenocallis littoralis has been known as a centuries-old remedy for cancer in the TM of the Mayan people of South America [2] . In southern Africa, Amaryllis belladonna, Boophone disticha and Crinum delagoense have been indicated for cancer remediation by the indigenous Sotho, Xhosa and Zulu people [3] . Furthermore, there is substantive evidence for the early use of the Amaryllidaceae in the Mediterranean basin as recorded by Hippocrates who recommended the "oil of narcissus" (Narcissus poeticus) for uterine cancers [4] . Given this substantial indigenous knowledge, efforts to unravel the chemical basis to these effects were slow in the making, with significant progress only being made in the latter years of the twentieth century [4] [5] [6] [7] . Such studies have identified the alkaloid constituents of the Amaryllidaceae [8] [9] [10] [11] as chiefly liable for its cytotoxic effects [4] [5] [6] [7] . Although the family is endowed with a significant array of alkaloid structural diversity (1-11) (Scheme 1), all of its members can be traced back to the common biogenetic precursor norbelladine (11) [8] [9] [10] [11] . The search for the key cytotoxic targets within the Amaryllidaceae was also bolstered by the discovery of a significant number of plant-derived products from other families which have reached the clinical end of the market in cancer chemotherapy [12] . To this extent, the phenanthridones of the Amaryllidaceae exemplified by pancratistatin (9) and narciclasine (10) have shown most promise and have been earmarked for commercial development [4] .
Although cytotoxic effects have been commonly observed for alkaloids across the Amaryllidaceae, the most active constituents are to be found within the lycorane, crinane and phenanthridone groups [4] [5] [6] [7] . Moreover, the basic phenanthridine nucleus from a pharmacophoric perspective is a discerning structural feature of these three antiproliferative alkaloid groups [4] [5] [6] [7] . Lycorine (1) was the first alkaloid identified in the Amaryllidaceae and was recognized as a cytotoxic substance by researchers at the NCI as early as the 1920s [6] . Its diagnostic structural feature is the N to C-4 ethyl tether added onto the existing phenanthridine framework [6] . To date, around 150 natural and semi-synthetic lycorine alkaloids have been assayed in almost 100 cancer cell lines [6] . In terms of potency, natural congeners of the group such as lycorine (1) and pseudolycorine (12) are consistently the most active in cell line assays, although semi-synthetically derived analogs such as 1,2-bis-allyllycorine (13) are amongst the most potent (IC 50 0.03 M in U373 human glioblastoma) [6] .
In the case of crinane alkaloids, the ethyl tether bridges the N to C-10b positions, giving rise to two stereo-defined subgroups; and -crinanes [5] . The latest statistics show that around 60 crinane alkaloid representatives have been subjected to cytotoxicity screening against the same number of cancer cell lines [5] . Crinamine (14) , haemanthamine (15) and haemanthidine (16) are the most common cytotoxic targets of the -series, whilst ambelline (17) and buphanisine (18) are common targets belonging to the series [5] . Haemanthamine was identified as the most active crinane alkaloid in human cancers with an ED 50 of 0.3 g/mL against HT-1080 fibrosarcoma cells [5] .
Of all three cytotoxic alkaloid groups, a significant amount of progress has been seen for the phenanthridone group emanating from the entry of pancratistatin (9) and narciclasine (10) into clinical trials [4] . These key compounds exhibited impressive mean IC 50 values of 0.26 and 0.046 M, respectively, in the NCI sixty cell line screen [4] . Nonetheless, SAR studies involving around 100 natural and semi-synthetic phenanthridone analogs have identified several targets with better potencies, such as 1-Obenzoylpancratistatin (19) (IC 50 0.23 nM in NCI-H460 human lung cancer) [4] . Thus, the foundation supporting the claim of Amaryllidaceae alkaloids in the clinical arena has been fortified via convincing in vitro antiproliferative data gathered over the past four decades [4] [5] [6] [7] . Surprisingly, this overwhelming evidence has not met with similar vigor via parallel in vivo studies, which is a significant hurdle to overcome in the clinical realm. This review seeks to highlight such studies carried out in vivo to support the cytotoxic effects observed for Amaryllidaceae alkaloids in vitro. In addition to the lead information gathered from ethnic medicine [1] , the initial findings on the in vitro and in vivo cytotoxic effects of Amaryllidaceae plant extracts were significant in steering efforts in the bioassay-guided isolation direction [4] [5] [6] [7] . To this extent, early work by Fitzgerald et al. (1958) at the NCI uncovered the in vivo cytotoxic effects of 66 species from 28 genera of the Amaryllidaceae [13] . In the study, CAF 1 mice (F1 hybrid of BALB/c female and A/J male) bearing sarcoma 37 (S-37) tumors were administered a single subcutaneous dose of the aqueous plant extract or alkaloid contralateral to the site of the tumor [13] . The mice were killed by cervical dislocation 24 h after injection and the tumors examined grossly for evidence of hemorrhage and necrosis compared with tumors in untreated control mice [13] . The results showed that majority of the plants exhibited negligible antitumor effects since their minimum effective doses (MEDs) were > 1000 g/g [13] . However, Rhodophiala chilensis (75 g/g), Hymenocallis caribaea (200 g/g), Hymenocallis occidentalis (250 g/g), Leucojum aestivum (300 g/g) and Lycoris incarnata (400 g/g) were noted for good activities. Similarly, LD 50 s > 1000 g/g were determined for the majority of plants against S-37 tumors, with the exception of Amaryllis belladonna (250 g/g), Nerine bowdenii (300 g/g), Brunsvigia hathor (350 g/g) and Hymenocallis caribaea (400 g/g) [13] .
Guided by this seminal work, Hartwell (1967) re-examined Amaryllis belladonna and showed that a bulb extract of the plant was highly active in the in vivo murine P-388 lymphocytic leukemia system, exhibiting a T/C (treatment/control) index as high as 203%
at a dosage of 50 mg/kg [14] . Charlson (1980) also examined Amaryllis belladonna in the P-388 lymphocytic leukemia system through which an active fraction was identified which increased the life span to 103% when applied at 50 mg/kg [15] . In the same study, an extract of Brunsvigia radulosa from a butanol fraction improved life span to 118% after treatment at 200 mg/kg [15] . Following this, followed a bioassay-guided approach to elucidate the active constituents of Amaryllis belladonna, which was also driven by the initial identification of an active fraction in the P-388 system which exhibited an in vivo T/C index of 70% (at 50 mg/kg) and ED 50 of 4.8 g/mL in vitro [16] . Similarly, were guided by an active fraction which had a T/C index of 131% (at 25 mg/kg) and ED 50 of 0.17 g/mL in the phytochemical analysis of Zephyranthes grandiflora [17] . In the phytochemical study of Pancratium littorale, Pettit et al. (1986) were again directed by an active fraction identified during the isolation sequence which exhibited a T/C index of 153% (at 75 mg/kg) in the P-388 in vivo system with a corresponding ED 50 of 0.33 g/mL in vitro [18] .
Thi Ngoc Tram et al. (1999) examined the effects of extracts of the Vietnamese plant Crinum latifolium on human and mouse peripheral blood T-lymphocytes [19a] . For the in vitro assay, peripheral blood mononuclear cells (PBMCs) were obtained from healthy human subjects and examined against aqueous extracts of Crinum latifolium adjusted to a final concentration of 5 mg/mL [19a] . In the event, there was a notable stimulatory effect on both CD3+T-cell and CD4+T-cell activity in the PBMCs as early as 24 h following incubation with both hot and cold water extracts [19a] . In vivo effects of Amaryllidaceae alkaloids Natural Product Communications Vol. 11 (1) 2016 123
CD4+T helper cells are white blood cells that are an essential part of the human immune system [19b] . They are referred to as CD4+T cells because they express the CD4 (cluster of differentiation 4) glycoprotein on their surface and are activated by peptide antigens by MHC (major histocompatibility complex) class II molecules which are expressed on the surface of antigen-presenting cells (APCs) [19b] . Once activated, they divide rapidly and secrete small proteins called cytokines that regulate or assist in the active immune response [19b] . On the other hand, CD3 is initially expressed in the cytoplasm of pro-thymocytes, the stem cells from which T-cells arise in the thymus [19c] . The presence of CD3 at all stages of Tcell development makes it a useful immuno-histochemical marker for T-cells [19c] . In the same study, Thi Ngoc Tram et al. (1999) showed that the Crinum latifolium extracts also stimulated lymphocyte proliferation in BALB/c mice [19a] . To this effect, lymphocytosis and a strong activation of lymphocytes to lymphoblasts were observed in peripheral blood smears taken under both acute (24 h) and chronic (6-15 days) experimental conditions [19a] . A further investigation by Thi Ngoc Tram et al. (2001) involved ascertaining the effects of Crinum latifolium extracts on tumors induced by 20-methylcholanthrene in Wistar mice [20] . In this case, tumors were established in the mice by the third month of introduction of the carcinogen and histological examination showed that they were of the sarcoma class-type [20] . The results revealed that control mice fed normal water survived an average of 38.6 days compared to test subjects administered the Crinum latifolium decoctions, in which case survival was on average 67.6 days representing a 75% improvement in life-extension [20] .
The examination of the in vivo cytotoxic effects of Amaryllidaceae alkaloids was initiated by Fitzgerald et al. in 1958 in the selfsame study that uncovered the effects of extracts of 66 species [13] . Of the 16 alkaloids screened, only lycorine (1) and lycorine hydrochloride (20) exhibited positive effects in the S-37 in vivo system at 100 and 75 g/g respectively (Table 1) , with the corresponding LD 50 s in each case shown to be exactly twice these values [13] . Galanthamine (3), ambelline (17) and buphanidrine (21) (Scheme 1) were particularly toxic to the CAF 1 mice with LD 50 s of 12, 3 and 4 g/g, respectively [13] . With the exception of galanthamine, all of these alkaloids have since been shown to be in vitro cytotoxic agents [5, 6] . Furthermore, the result for galanthamine is in context noteworthy since it is a present-day Alzheimer's drug not known for cytotoxic effects either in vitro or in vivo [21] .
Following this first report, Ceriotti (1967) examined the in vivo cytotoxic effect of narciclasine (10) which was described as a novel constituent of the genus Narcissus [22a] . As such, narciclasine was shown to be an antimitotic substance when administered orally and via intraperitoneal or subcutaneous injection to mice infected with S-180 [22a] . To this effect, a drastic decline in the number of mitoses was seen in the sarcoma cells 2 h after injection with a 0.9 mg/kg dose, with a 4 h treatment being sufficient to completely eradicate mitoses [22a] . As the dosage was increased, the mitoses disappeared more rapidly and disrupted cells with globular clumps of chromatin appeared more frequently [22a] . From an analysis of the observed antimitotic effects, it was apparent that narciclasine behaved like a metaphasic poison with mitoclasic activity especially at high doses [22a] . An LD 50 of 5 mg/kg was determined via the subcutaneous injection route [22a] . By contrast, Piozzi et al. (1968) in further investigation of the genus Narcissus showed that narciprimine (22) lacked the antimitotic activity earlier ascribed to narciclasine [22b]. Both narciclasine and narciprimine have since emerged as potent in vitro cytotoxic agents, with narciclasine in particular making significant progress from a clinical perspective [4] .
During the early 1970s there was significant interest in the Amaryllid Narcissus tazetta L. due to the potent cytotoxic effects detected for two of its constituents; pseudolycorine (12) and an unidentified alkaloid [23] . For the in vivo procedure, pseudolycorine and the residual alkaloid were evaluated against the standard drugs cyclophosphamide, vincristine and 6-mercaptopurine for antileukemic activity in Rauscher leukemia virus-infected BALB/c mice for durations lasting up to three weeks [23a] . The results showed that pseudolycorine and the residual alkaloid at MNTDs (maximum nontoxic doses) of 10 and 50 mg/kg prolonged life span by 102% and 132%, respectively, over controls [23a] . These were markedly superior to life span prolongations induced by cyclophosphamide (57%), vincristine (53%) and 6-mercaptopurine (78%) at MNTDs of 10, 0.15 and 30 mg/kg, respectively [23a] . In addition, pseudolycorine (12) and all three standards at twice their MNTDs decreased spleen weights and the number of nucleated blood cells, whilst only pseudolycorine and vincristine decreased viral titer in the plasma [23a] . This indicated that pseudolycorine and vincristine manifested their influence in Rauscher leukemia mice via both antitumor as well as antiviral effects [23a] .
A further investigation by Furusawa et al. (1972) showed that pseudolycorine (12) and the residual alkaloid from Narcissus tazetta L. were as effective under long-term administration (6-10 weeks)
[23b] as they were under short-term treatment (3 weeks) [23a] of Rauscher leukemia in BALB/c mice. To this extent, the average prolongation of median survival time (MST) over the control was 94% for pseudolycorine and 147% for the residual alkaloid, both at their maximum nontoxic doses [23b] . Corresponding values of 64%, 33% and 40% were observed for cyclophosphamide, vincristine and 6-mercaptopurine, respectively [23b]. Interestingly, combinations of the residual alkaloid with cyclophosphamide or 6mercaptopurine had a pronounced synergistic effect, with a prolongation of 210% and 160% seen in the former and latter cases respectively [23b]. Furthermore, the residual alkaloid was shown to exhibit low toxicity allowing for an effective dose to be administered for as long as 10 weeks without impairment to the immune and interferon natural defense systems [23b]. In addition, the residual alkaloid did not impair humoral antibody production in the leukemic mice compared to the standard drugs which were immunosuppressive during long-term treatment [23b].
In continuation of these findings Inspired by their findings in the 1970s, Furusawa et al. (1980) began the new decade with a cytotoxicity study involving members of most structural groups of the Amaryllidaceae in vitro against NIH/3T3 mouse embryonic fibroblasts and in vivo against Rauscher leukemia in BALB/c mice [24] . Of the twenty-four alkaloids examined in vitro eight were noted for potent activities, including narciclasine (10) (MTD 0.005 g/mL), pretazettine hydrochloride (23), precriwelline hydrochloride (24), 6-hydroxycrinamine methiodide (25) (MTDs 0.05 g/mL, respectively), lycorine (1), crinamine (14) , haemanthamine (15) and 6-hydroxycrinamine (26) (MTDs 0.2 g/mL, respectively) [24] . In the in vivo assay, pretazettine hydrochloride (23) emerged as the target of choice exhibiting a median survival time (MST) of 89 days in Rauscher leukemia BALB/c mice and an impressive prolongation of life span of 141% over untreated controls (Table 1 ) [24] . Surprisingly, the potent in vitro activity of narciclasine (10) could not be transferred to the in vivo medium where its prolongation of life span was only 31% [24] , although it could be argued that this disparity may be the effect of cell line specificity.
Pettit and co-workers followed bioassay-guided approaches to target the active constituents of the three Amaryllid species (Amaryllis belladonna, Zephyranthes grandiflora and Pancratium littorale) described above [16] [17] [18] . In particular, Amaryllis belladonna on two occasions prior to the work of [16] had already been established as a cytotoxic plant with potent in vitro and in vivo activity in the P-388 lymphocytic leukemia assay [14, 15] . With the exception of undulatine (27), showed that ambelline (17), acetylcaranine (28) and anyhydrolycorinium chloride (29) exhibited potent activities in vitro against P-388 cells with ED 50 s of 1.6, 0.23 and 1.4 g/mL, respectively [16] . However, in vivo only anyhydrolycorinium chloride exhibited prominent activity in the P-388 system with a T/C index of 164% at 10 mg/kg [16] . Although lycorine (1) was not identified during the investigation by involving Amaryllis belladonna bulbs collected in Australia [16] , Charlson (1980) had identified this alkaloid in the same species from a collection made in South Africa [15] . On this occasion, lycorine exhibited low antileukemic activity in vivo (35% increase in life span at a dose level of 75 mg/kg) in the P-388 lymphocytic leukemia system [15] . Similarly, isolated pancratistatin (9) from a sizeable collection of Zephyranthes grandiflora bulbs and demonstrated its potent activity in vitro (ED 50 < 0.01 g/mL) and in vivo (T/C 135%-150% at dosages of 0.78-3.1 mg/kg) [17] . In addition to pancratistatin (9) and narciclasine (10), Pettit et al. (1986) also identified lycoricidine (30) as an in vitro and in vivo antineoplastic agent in Pancratium littorale with an ED 50 of 0.02 g/mL and T/C index of 161% (at 12.5 mg/kg) [18] . In addition, pancratistatin was shown to have significant effects in vivo against the M5076 ovary sarcoma cell line (T/C index of 153-184% at 0.38-3.0 mg/kg) [18] .
During the mid-to-late 80s Ghosal et al. carried out a significant amount of work on the cytotoxic effects of alkaloid constituents identified in three Amaryllid species of the Indian subcontinent [25] . Initially, kalbretorine (31) and kalbreclasine (32) (Schemes 1 and 2) were identified as novel constituents in Haemanthus kalbreyeri and examined for cytotoxic effects in S-180 sarcoma cells [25a] . In vitro, the viability of cells was diminished to 32.5% after only 3 h following treatment with 10 mM kalbretorine [25a] .
Furthermore, kalbreclasine (32) in doses of 20 g produced mitogenic activation of splenic lymphocytes in healthy adult male DBA/2 mice with a stimulation index (SI) of 3.1, which was comparable to that observed for the known mitogen Concanavalin A (SI 3.0 at 5 g dosages) [25a] . then examined the in vitro and in vivo cytotoxic effects of four lycorine constituents (1, 33, 34, 35) (1), pratorimine (41) and criasiaticidine A (42) (Schemes 1 and 2) [27a] . As such, lycorine was shown to be the most active of the three with in vitro ED 50 s of 0.3 and 0.5 g/mL against Meth-A sarcoma and Lewis lung carcinoma (LLC) cells, respectively [27a] . In the same instance, ED 50 s for the remaining two alkaloids ranged from 3.2 to > 10 g/mL in both cell lines [27a] . In view of the potent antitumor activity established in vitro for lycorine, Min et al. (2001) in the same investigation explored these effects in vivo using BDF-1 mice subcutaneously implanted with LLC cells [27a] . The results showed that treatment with lycorine at 10 mg/kg/day over a 14-day period produced a notable decrease in tumor size (T/C index 80.5%) [27a] . Furthermore, at the same dosage lycorine decreased body weight by approximately 5% of the control, which nevertheless could be rapidly overcome by halting the treatment [27a] .
Based on the in vitro cytotoxic effects observed for lycorine (1) . In the assay, B16F10 melanoma cells were orthotopically grafted into the brains of mice in order to mimic melanoma brain metastases, a feature that is common in melanoma patients and contributes to poor prognoses [27d]. Initially, intravenous injection of lycorine at 5, 10, 20, 40 or 80 mg/kg once-daily into healthy B6D2F1 mice showed that no adverse effects were manifested during the treatment period stretching 28 days [27d] . Subsequently it was demonstrated that lycorine significantly increased the survival of B16F10 melanomabearing mice when administered intravenously thrice-weekly at 40 mg/kg during three weeks of consecutive treatment ( In the same instance, the reference melanoma drug cisplatin at its MTD of 5 mg/kg failed to provide significant therapeutic benefit [27d]. Furthermore, it was concluded that lycorine is able to cross the blood-brain barrier because it significantly increased the survival of mice bearing melanoma brain-related metastases, even though it was administered intravenously [27d]. 
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A further two studies of in vivo cytotoxic effects of lycorane alkaloids involved the quaternary salt lycorine hydrochloride (20) [27e,f]. The only previous in vivo cytotoxic result for lycorine hydrochloride in cancer cells was found in the report by Fitzgerald et al. (1958) wherein at 75 g/g it was active against S-37 tumors in CAF 1 mice [13] . In comparison to lycorane alkaloids, fewer studies have addressed the in vivo cytotoxic effects of crinane alkaloids. Nonetheless, early on Fitzgerald et al. (1958) had examined the in vivo effects of crinine (2), haemanthamine (15) , haemanthidine (16) , ambelline (17) and buphanidrine (21) , showing that none of these were active in CAF 1 mice implanted with S-37 tumors [13] . However, Furusawa et al. (1980) noted that haemanthamine (15) and 6hydroxycrinamine (26) exhibited MSTs of 42 and 64 days, respectively, in BALB/c mice infected with Rauscher leukemia, with 31-36% prolongation of life span over controls [24] . As referred to above, observed that neither ambelline (17) nor undulatine (27) were active in the in vivo P-388 lymphocytic leukemia system [16] . In addition to this, the crinanes crinafoline (36), crinafolidine (37) and crinafoline methochloride (38) (Scheme 2) as shown by Ghosal and Singh (1986) exhibited appreciable levels of activity against S-180 tumors in Swiss mice [25c].
Around the same time, Alarcón et al. (1986) examined the cytotoxic effects of maritidine (43) and hippeastidine (44), two crinane alkaloid constituents of the South American Amaryllid Hippeastrum anunuca [28a] . As such, both alkaloids exhibited pronounced in vitro antineoplastic activity against KB human oral epidermoid carcinoma with ED 50 s of 0.51 and 0.27 g/mL, respectively [28a] . Following this, both compounds were screened for clastogenic activity in the micronucleus test [28a] . Formation of secondary nuclei (or micronuclei) is a characteristic morphological feature observed in cells exposed to clastogenic substances [28a] . The micronucleus test serves as an efficient tool to reliably establish the genotoxicity of a cytostatic compound [28a] . In the assay, bone marrow taken from the femur of BALB/c mice was examined for evidence of micronuclei formation 30 h after intraperitoneal treatment with either distilled water, adriamycin ( Although the identification of pancratistatin (9) and narciclasine (10) were made almost two decades apart, it was the discovery of the former in 1984 by Pettit et al. [17] as a potent in vitro and in vivo antineoplastic agent that reignited the interest of the pharmacology community in the potential of phenanthridones as chemotherapeutics. As mentioned above, Ceriotti (1967) had initially described narciclasine (10) as an antimitotic substance with significant cytotoxic effects in vivo against S-180 sarcoma tumors in mice [22a] . Following the findings of [17] , most research efforts focused on in vitro studies of phenanthridone alkaloids [4], while pancratistatin and narciclasine in the interim were shuttled into clinical trials [29a] . Although the phytochemical platform has not afforded many natural phenanthridone alkaloids for structure-activity study purposes [4] , this deficit has largely been overcome via synthetic endeavors stimulated by the interesting and . Furthermore, narciclasine was seen to be a selective cytotoxic agent as its effects on normal fibroblasts (IC 50 s ≥ 317 nM) were markedly weaker than on tumor cells [29e]. In addition, its antiproliferative effect on human umbilical vein endothelial cells (HUVECs) (IC 50 s 87-94 nM) was closer to that observed in tumor cells, highlighting its potential as an antiangiogenic agent [29e]. In the in vivo study, immuno-compromised Nu/Nu nude mice were orthotopically grafted with A549 NSCLC cells either into the lungs or brains (to mimic brain metatheses) [29e]. In the lung model, a single intravenous dose of narciclasine at 1 mg/kg once-per-week for five consecutive weeks did not increase the survival of mice compared to control animals [29e]. In contrast, narciclasine (10) (Scheme 1) under the same schedule produced a dramatic prolongation of life span in mice containing A549 brain grafts [29e]. This therefore highlighted an important clinical property of narciclasine: its ability to cross the blood-brain barrier [29e]. Ingrassia et al. (2009) then expanded on their observations in the A549 brain xenograft to include a further two brain cell lines, including Hs683 and GL19 glioblastoma in which narciclasine was shown to exhibit negligible effects [29e]. In the same instance the 7-O--D-glucosyl analog (46) significantly increased the survival of orthotopic xenograft bearing mice when administered (1 mg/kg) orally or intravenously five times a week (Monday-Friday) over three weeks [29e]. The dosage of 1 mg/kg was well-tolerated and shown to produce no adverse effects in test animals not exposed to tumors and was thus defined as the no adverse effect level (NOAEL) [29e]. In addition, narciclasine (at 50 nM) significantly modified cell migration levels in U373, Hs683 and GL19 cells, which were also more pronounced in these glioblastoma cells than in normal Ccd-25-Lu fibroblasts [29f] . For the in vivo study, Hs683 (2 x 10 5 cells) and GL19 (4 x 10 5 cells) glioblastoma were orthotopically xenografted into the brains of six-week old nude mice producing invasive tumors within 5-7 days post tumor-grafting [29f]. To this effect, intravenous (1 mg/kg/twice per week/5 weeks) or oral (1 mg/kg/once per week/5 weeks) administration of narciclasine (10) significantly increased the survival of GL19 tumor-infected mice by almost twice that of control animals, which was somewhat attenuated for Hs683-infected mice [29f]. It was also shown that
In vivo effects of Amaryllidaceae alkaloids Natural Product Communications Vol. 11 (1) . Under these conditions, pancratistatin was also shown to be more effective than paclitaxel which was administered at the lower dosage of 0.5 M [30i]. Furthermore, PBMCs from the blood of healthy volunteers were unaffected by such treatments with pancratistatin, highlighting its chief characteristic as a selective apoptotic agent [30i].
These . Tumors were allowed to grow for 4 weeks after which animals were treated intra-tumorally with vehicle (5 L DMSO in PBS) or pancratistatin (3 mg/kg) four times per week for three weeks (Table 1) [30j]. In this way it was shown that after the treatment window, the average tumor volume was approximately 50% less in pancratistatin-treated mice than those exposed to the vehicle [30j]. Furthermore, the average body weight of animals did not vary significantly between treatment groups indicating no overt toxic effects for pancratistatin [30j]. In addition, there were no obvious signs of stress such as redness or swelling at the injection site, or change in activity/behaviour of animals receiving pancratistatin compared to controls [30j]. In summary, Amaryllidaceae alkaloids have proved to be highly useful and versatile targets for in vitro and in vivo cytotoxic model study purposes. Although the findings from in vitro observations are extensive, information gathered from in vivo experimental settings have been most valuable, particularly as a proof of concept from a clinical standpoint. These effects have been demonstrated across members of the three classically-defined cytotoxic Amaryllidaceae alkaloid groups, including lycoranes, crinanes and phenanthridones. Potent in vivo cytotoxic effects against cancer cells were uncovered for several members of these groups, often with better activities than standard chemotherapeutic drugs. Often accompanying these effects were exceptionally high selectivities and tolerability as well as minimal adverse side effects. A chief characteristic of these molecules is their ability to induce apoptosis selectively in cancer cells than in normal cells. In this regard, the phenanthridones of the Amaryllidaceae such as pancratistatin and narciclasine have experienced considerable success as cell line specific cytotoxic entities from which a clinical target is likely to evolve. This forecast is promising given that both of these alkaloids have met with reasonable success in clinical trials. In the interim, new targets continue to be afforded from strident efforts in the phytochemical and synthetic arenas.
